Nuvectis Pharma, Inc. (NVCT) Financial Statements
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NVCTNuvectis Pharma, Inc.Follow NVCT — free
—
Price chart with a free account
- Market cap
- 653.3M
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Research & development | 13.2 | 15.4 | 12.9 | 18.2 | 19.7 | |
| Operating income | -19.2 | -22.9 | -19.8 | -27.6 | -28.9 | |
| Pre-tax income | -19.1 | -22.3 | -19.0 | -26.4 | -27.8 | |
| Net income | -19.1 | -22.3 | -19.0 | -26.4 | -27.8 | |
| Diluted EPS ($) | -1.51 | -1.43 | -1.11 | -1.32 | -1.31 | |
| Diluted shares (mn) | 12.7 | 15.6 | 17.1 | 21.8 | — |
USD millions · SEC XBRL
Nuvectis Pharma, Inc. — questions
- What is Nuvectis Pharma, Inc.'s net income?
- -$27.8M over the twelve months to 2026-06-30.
- What are Nuvectis Pharma, Inc.'s diluted earnings per share?
- $-1.31 over the twelve months to 2026-06-30.
Every figure on this page comes from Nuvectis Pharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.